Document is current
Any future updates will be listed below
-
Authors
Condit, Paige E.
Guillet, Ronnie
Kaluarachchi, Dinushan
Griffin, Russell L.
Menon, Shina
Askenazi, David J.
Harer, Matthew W.
-
Funding
Funding for this research was provided by:
Nuwellis
- License Information
-
More Information
Article History
Received: 22 December 2024
Accepted: 10 March 2025
First Online: 19 March 2025
Declarations
:
: This is a retrospective observational study using existing data. There were no study intervention and the existing data was received and used in a de-identified manner to protect subject privacy. The original PENUT trial received ethics approvals from all participating centers with the University of Washington institutional review board (IRB) serving as the central institutional review board.
: Not applicable.
: For full disclosure, we provide here an additional list of other author’s commitments and funding sources that are not directly related to this study: In the last 24 months, David J Askenazi has consulted with Nuwellis, Seastar, and Abbott. Over the last 24 months, his institution has received funding for education and research that is not related to this project from Nuwellis, Bioporto, Leadiant and Seastar. He has financial interests in patent/innovations pending in the area of kidney support therapies and urine collection devices. He is the Founder and Chief Scientific Officer for Zorro-Flow Inc. Ronnie Guillet: Ronnie Guillet is a stockholder in Zorro-Flow Inc. Dinushan Kaluarachchi: Dinushan Kaluarachchi serves as a consultant for ONY Biotech.
: The authors declare no competing interests.
